Company Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.
Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial.
Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran.
It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2002 |
| IPO Date | May 28, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,100 |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., MBChB |
Contact Details
Address: 675 West Kendall Street, Henri A. Termeer Square Cambridge, Massachusetts 02142 United States | |
| Phone | (617) 551-8200 |
| Website | alnylam.com |
Stock Details
| Ticker Symbol | ALNY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178670 |
| CUSIP Number | 02043Q107 |
| ISIN Number | US02043Q1076 |
| Employer ID | 77-0602661 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yvonne L. Greenstreet M.B.A., MBChB | Chief Executive Officer and Director |
| Jeffrey V. Poulton M.B.A. | Chief Financial Officer and Executive Vice President |
| Dr. Akshay K. Vaishnaw M.D., Ph.D. | Chief Innovation Officer and Member of the Scientific Advisory Board |
| Dr. Pushkal P. Garg M.D. | Chief Medical Officer and Executive Vice President of Development and Medical Affairs |
| Tolga Tanguler M.B.A. | Executive Vice President and Chief Commercial Officer |
| Timothy J. Maines | Chief Technical Operations and Quality Officer |
| Dr. Kevin Joseph Fitzgerald Ph.D. | Senior Vice President, Head of Research and Chief Scientific Officer |
| Christine Regan Lindenboom | Senior Vice President of Investor Relations and Corporate Communications |
| Piyush Sharma J.D. | Chief Ethics and Compliance Officer |
| Evan Lippman M.B.A. | Chief Corporate Development and Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | ARS | Filing |
| Apr 1, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 1, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 144 | Filing |
| Feb 15, 2024 | 10-K | Annual Report |
| Feb 15, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |